Search results
Results from the WOW.Com Content Network
The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS), is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke and aid planning post-acute care disposition, though was intended to assess differences in interventions in clinical trials. The NIHSS was designed for the National ...
The new director of the NIH, James Shannon, a politically astute man who also had an ability to pick talented scientists, helped solidify what became "the golden years of science at NIH". [20] With Shannon, Fogarty, Hill, and Lasker working together, the NIH's budget as a whole increased more than tenfold between 1955 and 1965. [21]
If any one of the three tests shows abnormal findings, the patient may be having a stroke and should be transported to a hospital as soon as possible. The CPSS was derived from the National Institutes of Health Stroke Scale developed in 1997 at the University of Cincinnati Medical Center for prehospital use. [2]
The American Heart Association (AHA) is a nonprofit organization in the United States that funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke.
The Los Angeles Prehospital Stroke Screen (abbreviated LAPSS) is a method of identifying potential stroke patients in a pre-hospital setting. [ 1 ] Screening criteria
The National Stroke Association was a U.S.-based nonprofit organization working between the years 1984–2019 to reduce the incidence and impact of stroke, the fourth leading cause of death in the United States. The association delivered education and programs focused on prevention, treatment, rehabilitation, and support for all impacted by stroke.
In FY 2010, the NIH spent US$10.7bn (not including temporary funding from the American Recovery and Reinvestment Act of 2009) on clinical research, US$7.4bn on genetics-related research, US$6.0bn on prevention research, US$5.8bn on cancer, and US$5.7bn on biotechnology.
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It has become the most widely used clinical outcome measure for stroke clinical trials. [1] [2]